{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:04:58Z","timestamp":1789502698786,"version":"build-2803163510"},"reference-count":64,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["Department of Defense Idea Award, CA180425"],"award-info":[{"award-number":["Department of Defense Idea Award, CA180425"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017804","name":"City of Hope","doi-asserted-by":"publisher","award":["Department of Surgery Start-Up Grant - N\/A"],"award-info":[{"award-number":["Department of Surgery Start-Up Grant - N\/A"]}],"id":[{"id":"10.13039\/100017804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,3,9]]},"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Gastric cancer (GC) that metastasizes to the peritoneum is fatal. CF33 and its genetically modified derivatives show cancer selectivity and oncolytic potency against various solid tumors. CF33-hNIS and CF33-hNIS-antiPDL1 have entered phase I trials for intratumoral and intravenous treatments of unresectable solid tumors (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05346484\">NCT05346484<\/jats:ext-link>) and triple-negative breast cancer (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05081492\">NCT05081492<\/jats:ext-link>). Here, we investigated the antitumor activity of CF33-oncolytic viruses (OVs) against GC and CF33-hNIS-antiPDL1 in the intraperitoneal (IP) treatment of GC peritoneal metastases (GCPM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We infected six human GC cell lines AGS, MKN-45, MKN-74, KATO III, SNU-1, and SNU-16 with CF33, CF33-GFP, or CF33-hNIS-antiPDL1 at various multiplicities of infection (0.01, 0.1, 1.0, and 10.0), and performed viral proliferation and cytotoxicity assays. We used immunofluorescence imaging and flow cytometric analysis to verify virus-encoded gene expression. We evaluated the antitumor activity of CF33-hNIS-antiPDL1 following IP treatment (3\u00d710<jats:sup>5<\/jats:sup> pfu \u00d7 3 doses) in an SNU-16 human tumor xenograft model using non-invasive bioluminescence imaging.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CF33-OVs showed dose-dependent infection, replication, and killing of both diffuse and intestinal subtypes of human GC cell lines. Immunofluorescence imaging showed virus-encoded GFP, hNIS, and anti-PD-L1 antibody scFv expression in CF33-OV-infected GC cells. We confirmed GC cell surface PD-L1 blockade by virus-encoded anti-PD-L1 scFv using flow cytometry. In the xenograft model, CF33-hNIS-antiPDL1 (IP; 3\u00d710<jats:sup>5<\/jats:sup> pfu \u00d7 3 doses) treatment significantly reduced peritoneal tumors (p&lt;0.0001), decreased amount of ascites (62.5% PBS vs 25% CF33-hNIS-antiPDL1) and prolonged animal survival. At day 91, seven out of eight mice were alive in the virus-treated group versus one out of eight in the control group (p&lt;0.01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results show that CF33-OVs can deliver functional proteins and demonstrate effective antitumor activity in GCPM models when delivered intraperitoneally. These preclinical results will inform the design of future peritoneal-directed therapy in GCPM patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-006280","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T10:40:30Z","timestamp":1680691230000},"page":"e006280","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct05346484","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05081492","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Annie","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Surgery, City of Hope National Medical Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Surgery, City of Hope National Medical Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyambabu","family":"Chaurasiya","sequence":"additional","affiliation":[{"name":"Department of Surgery, City of Hope National Medical Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7692-8874","authenticated-orcid":false,"given":"Anthony K","family":"Park","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapeutics Program, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Surgery, City of Hope National Medical Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Surgery, City of Hope National Medical Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-In","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgery, City of Hope National Medical Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8136-2112","authenticated-orcid":false,"given":"Saul","family":"Priceman","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapeutics Program, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuman","family":"Fong","sequence":"additional","affiliation":[{"name":"Department of Surgery, City of Hope National Medical Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6676-0593","authenticated-orcid":false,"given":"Yanghee","family":"Woo","sequence":"additional","affiliation":[{"name":"Department of Surgery, City of Hope National Medical Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"2025100315211430000_11.4.e006280.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2025100315211430000_11.4.e006280.2","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000149300.28588.23"},{"key":"2025100315211430000_11.4.e006280.3","doi-asserted-by":"publisher","DOI":"10.1002\/jso.25639"},{"key":"2025100315211430000_11.4.e006280.4","doi-asserted-by":"crossref","DOI":"10.21037\/tgh.2019.05.02","article-title":"Multimodality management of locally advanced gastric cancer-the timing and extent of surgery","volume":"4","author":"Stewart","year":"2019","journal-title":"Transl Gastroenterol Hepatol"},{"key":"2025100315211430000_11.4.e006280.5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.21037\/jgo.2018.03.01","article-title":"Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification","volume":"9","author":"Chuang","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"2025100315211430000_11.4.e006280.6","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919877726","article-title":"First-line systemic therapy for advanced gastric cancer: a systematic review and network meta-analysis","volume":"11","author":"Cheng","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"2025100315211430000_11.4.e006280.7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","article-title":"The 30-year experience\u2014A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer","volume":"79","author":"Desiderio","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025100315211430000_11.4.e006280.8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.amjsurg.2022.01.024","article-title":"Patterns of gastric cancer metastasis in the united states","volume":"224","author":"Sirody","year":"2022","journal-title":"Am J Surg"},{"key":"2025100315211430000_11.4.e006280.9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.21037\/dmr-21-94","article-title":"Gastric adenocarcinoma peritoneal carcinomatosis: a narrative review","volume":"5","author":"Green","year":"2022","journal-title":"Dig Med Res"},{"key":"2025100315211430000_11.4.e006280.10","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10214882","article-title":"The burden of peritoneal metastases from gastric cancer: A systematic review on the incidence, risk factors and survival","volume":"10","author":"Rijken","year":"2021","journal-title":"J Clin Med"},{"key":"2025100315211430000_11.4.e006280.11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0035-1564431","article-title":"Peritoneal carcinomatosis from colon cancer: a systematic review of the data for cytoreduction and intraperitoneal chemotherapy","volume":"28","author":"Nadler","year":"2015","journal-title":"Clin Colon Rectal Surg"},{"key":"2025100315211430000_11.4.e006280.12","doi-asserted-by":"publisher","DOI":"10.1038\/nature13480"},{"key":"2025100315211430000_11.4.e006280.13","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3850"},{"key":"2025100315211430000_11.4.e006280.14","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-021-00826-w","article-title":"Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial","volume":"13","author":"Kim","year":"2021","journal-title":"Genome Med"},{"key":"2025100315211430000_11.4.e006280.15","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-017-0484-3","article-title":"Actionable gene-based classification toward precision medicine in gastric cancer","volume":"9","author":"Ichikawa","year":"2017","journal-title":"Genome Med"},{"key":"2025100315211430000_11.4.e006280.16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215382","article-title":"The epithelial and stromal immune microenvironment in gastric cancer: A comprehensive analysis reveals prognostic factors with digital cytometry","volume":"13","author":"Shen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025100315211430000_11.4.e006280.17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.884090","article-title":"A novel exosome-relevant molecular classification uncovers distinct immune escape mechanisms and genomic alterations in gastric cancer","volume":"13","author":"Lin","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025100315211430000_11.4.e006280.18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s12029-020-00419-7","article-title":"Prediction of peritoneal recurrence in patients with gastric cancer: a multicenter study","volume":"52","author":"Kus","year":"2021","journal-title":"J Gastrointest Cancer"},{"key":"2025100315211430000_11.4.e006280.19","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1245\/s10434-019-07624-0","article-title":"Gastric cancer peritoneal carcinomatosis risk score","volume":"27","author":"Ji","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2025100315211430000_11.4.e006280.20","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s10120-021-01160-1","article-title":"Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide dutch cohort","volume":"24","author":"Koemans","year":"2021","journal-title":"Gastric Cancer"},{"key":"2025100315211430000_11.4.e006280.21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10120-019-00978-0","article-title":"Peritoneal metastasis in gastric cancer: results from the German database","volume":"23","author":"Rau","year":"2020","journal-title":"Gastric Cancer"},{"key":"2025100315211430000_11.4.e006280.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"2025100315211430000_11.4.e006280.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70420-6"},{"key":"2025100315211430000_11.4.e006280.24","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S2468-1253(21)00313-7","article-title":"Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-asia): a randomised, multicentre, double-blind, phase 3 trial","volume":"6","author":"Xu","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025100315211430000_11.4.e006280.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61719-5"},{"key":"2025100315211430000_11.4.e006280.26","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100315211430000_11.4.e006280.27","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025100315211430000_11.4.e006280.28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"key":"2025100315211430000_11.4.e006280.29","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-318070"},{"key":"2025100315211430000_11.4.e006280.30","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10204649","article-title":"Immunotherapy for peritoneal metastases from gastric cancer: rationale, current practice and ongoing trials","volume":"10","author":"Ruiz Hisp\u00e1n","year":"2021","journal-title":"J Clin Med"},{"key":"2025100315211430000_11.4.e006280.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00175-3"},{"key":"2025100315211430000_11.4.e006280.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5"},{"key":"2025100315211430000_11.4.e006280.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0025"},{"key":"2025100315211430000_11.4.e006280.34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000505974","article-title":"Nivolumab in combination with irinotecan and 5-fluorouracil (FOLFIRI) for refractory advanced gastroesophageal cancer","volume":"98","author":"Rogers","year":"2020","journal-title":"Oncology"},{"key":"2025100315211430000_11.4.e006280.35","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3770"},{"key":"2025100315211430000_11.4.e006280.36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3232"},{"key":"2025100315211430000_11.4.e006280.37","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.109"},{"key":"2025100315211430000_11.4.e006280.38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.omtm.2021.12.002","article-title":"A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hnis-anti-PD-L1 to treat breast cancer","volume":"24","author":"Chaurasiya","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025100315211430000_11.4.e006280.39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jamcollsurg.2019.12.027","article-title":"Novel chimeric immuno-oncolytic virus CF33-hnis-antipdl1 for the treatment of pancreatic cancer","volume":"230","author":"Woo","year":"2020","journal-title":"J Am Coll Surg"},{"key":"2025100315211430000_11.4.e006280.40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41417-021-00350-4","article-title":"CF33-hnis-antipdl1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"2025100315211430000_11.4.e006280.41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.omto.2021.12.022","article-title":"Pet imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hnis-antipdl1","volume":"24","author":"Zhang","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"2025100315211430000_11.4.e006280.42","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.omto.2019.04.001","article-title":"A novel chimeric poxvirus encoding hnis is tumor-tropic, imageable, and synergistic with radioiodine to sustain colon cancer regression","volume":"13","author":"Warner","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"2025100315211430000_11.4.e006280.43","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1483-x","article-title":"Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose","volume":"16","author":"O\u2019Leary","year":"2018","journal-title":"J Transl Med"},{"key":"2025100315211430000_11.4.e006280.44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.omto.2018.03.001","article-title":"A novel oncolytic chimeric orthopoxvirus encoding luciferase enables real-time view of colorectal cancer cell infection","volume":"9","author":"O\u2019Leary","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"2025100315211430000_11.4.e006280.45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41417-019-0114-x","article-title":"A chimeric poxvirus with J2R (thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models","volume":"27","author":"Chaurasiya","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"2025100315211430000_11.4.e006280.46","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1729300","article-title":"Oncolytic poxvirus CF33-hnis-\u03b4f14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model","volume":"9","author":"Chaurasiya","year":"2020","journal-title":"Oncoimmunology"},{"key":"2025100315211430000_11.4.e006280.47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013985","article-title":"Generation of novel bone forming cells (monoosteophils) from the cathelicidin-derived peptide LL-37 treated monocytes","volume":"5","author":"Zhang","year":"2010","journal-title":"PLoS One"},{"key":"2025100315211430000_11.4.e006280.48","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1380764","article-title":"Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer","volume":"7","author":"Priceman","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100315211430000_11.4.e006280.49","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60327-321-3_4"},{"key":"2025100315211430000_11.4.e006280.50","doi-asserted-by":"publisher","DOI":"10.2144\/000112515"},{"key":"2025100315211430000_11.4.e006280.51","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-022516-034125"},{"key":"2025100315211430000_11.4.e006280.52","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-7-5","article-title":"Expression of the Na+\/l-symporter (NIS) is markedly decreased or absent in gastric cancer and intestinal metaplastic mucosa of Barrett esophagus","volume":"7","author":"Altorjay","year":"2007","journal-title":"BMC Cancer"},{"key":"2025100315211430000_11.4.e006280.53","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.trecan.2021.03.003","article-title":"Extracellular and nuclear PD-L1 in modulating cancer immunotherapy","volume":"7","author":"Xiong","year":"2021","journal-title":"Trends Cancer"},{"key":"2025100315211430000_11.4.e006280.54","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020495","article-title":"A Sox2 reporter system identifies gastric cancer stem-like cells sensitive to monensin","volume":"12","author":"P\u00e1dua","year":"2020","journal-title":"Cancers"},{"key":"2025100315211430000_11.4.e006280.55","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2005.37.1.1"},{"key":"2025100315211430000_11.4.e006280.56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"2025100315211430000_11.4.e006280.57","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28373"},{"key":"2025100315211430000_11.4.e006280.58","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008243606668"},{"key":"2025100315211430000_11.4.e006280.59","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00155","article-title":"Immunotherapeutic potential of oncolytic vaccinia virus","volume":"4","author":"Thorne","year":"2014","journal-title":"Front Oncol"},{"key":"2025100315211430000_11.4.e006280.60","doi-asserted-by":"crossref","DOI":"10.1186\/1756-9966-33-2","article-title":"A novel oncolytic viral therapy and imaging technique for gastric cancer using A genetically engineered vaccinia virus carrying the human sodium iodide symporter","volume":"33","author":"Jun","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"2025100315211430000_11.4.e006280.61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0244"},{"key":"2025100315211430000_11.4.e006280.62","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018054","article-title":"Efficacy and safety of anti-PD-1\/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2025100315211430000_11.4.e006280.63","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0405"},{"key":"2025100315211430000_11.4.e006280.64","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"J Immunother Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-006280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:21:26Z","timestamp":1759530086000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-006280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":64,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,5]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1136\/jitc-2022-006280"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-006280","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}